The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Bona named director of Benign Hematology at Smilow Cancer Hospital

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Robert Bona was named professor of medicine (hematology) and inaugural director of the Benign Hematology Program at Smilow Cancer Hospital. He will also join as Medical Director of the Hemophilia Treatment Center for the Pediatric Hematology & Oncology Program at Smilow Cancer Hospital.

Bona will begin in his roles July 1.

Bona has been serving as a part-time member of the hematology department at Yale Cancer Center for the last three years.

Bona joins Yale from Quinnipiac University where he is a founding faculty member and professor of medical sciences at the Frank H. Netter MD School of Medicine. Bona has led several research studies, clinical trials, and care innovations to advance the treatment of blood diseases.

Table of Contents

YOU MAY BE INTERESTED IN

Regulatory News

Makary vows to speed up drug approvals and end FDA’s “cozy” relationship with industry
Commissioner promises to protect scientific integrity while bringing in “fresh” MAHA ideas

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
By Claire Marie Porter
Guest Editorial

Regulation must keep up with scientific advances

The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.
By Richard M. Goldberg
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account